The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Abstract
CD8+ cytotoxic T lymphocytes (CTLs) are preferred immune cells for targeting cancer. During cancer progression, CTLs encounter dysfunction and exhaustion due to immunerelated tolerance and immunosuppression within the tumor microenvironment (TME), with all favor adaptive immune‐resistance. Cancer‐associated fibroblasts (CAFs), macrophage type 2 (M2) cells, and regulatory T cells (Tregs) could make immunologic barriers against CD8 + T cell‐mediated antitumor immune responses. Thus, CD8 + T cells are needed to be primed and activated toward effector CTLs in a process called tumor immunity cycle for making durable and efficient antitumor immune responses. The CD8 + T cell priming is directed essentially as a corroboration work between cells of innate immunity including dendritic cells (DCs) and natural killer (NK) cells with CD4 + T cells in adoptive immunity. Upon activation, effector CTLs infiltrate to the core or invading site of the tumor (so‐called infiltrated–inflamed [I–I] TME) and take essential roles for killing cancer cells. Exogenous reactivation and/or priming of CD8 + T cells can be possible using rational immunotherapy strategies. The increase of the ratio for costimulatory to coinhibitory mediators using immune checkpoint blockade (ICB) approach. Programmed death‐1 receptor (PD‐1)–ligand (PD‐L1) and CTL‐associated antigen 4 (CTLA‐4) are checkpoint receptors that can be targeted for relieving exhaustion of CD8 + T cells and renewing their priming, respectively, and thereby eliminating antigen‐expressing cancer cells. Due to a diverse relation between CTLs with Tregs, the Treg activity could be dampened for increasing the number and rescuing the functional potential of CTLs to induce immunosensitivity of cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 3×
“A point here is that pre‐existing CTLs are required for regression of tumors using PD‐1 blockade approach (Tumeh et al., 2014).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
Remodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367 · cited 1×
“ECM degradation mediated by MMPs could also induce secretion of antiangiogenic factors (Bonnans et al., 2014).”
BackgroundMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Cited by
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity
Wang, J. X., Choi, S. Y. C., Niu, X., Kang, N., Xue, H., Killam, J., & Wang, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218363 · Cited by 460
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Xie, Z., Peng, M., Lu, R., Meng, X., Liang, W., Li, Z., Qiu, M., Zhang, B., Nie, G., Xie, N., et al. (2020) · Light: Science & Applications · doi:10.1038/s41377-020-00388-3 · Cited by 265
Pang, K., Shi, Z.-D., Wei, L.-Y., Dong, Y., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J.-J., Chen, Y.-A., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 260
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 256
Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01600-6 · Cited by 256
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 256
Mechanism of interaction between autophagy and apoptosis in cancer
Das, S., Shukla, N., Singh, S. S., Kushwaha, S., & Shrivastava, R. (2021) · Apoptosis · doi:10.1007/s10495-021-01687-9 · Cited by 255
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
Local heroes or villains: tissue-resident memory T cells in human health and disease
Sasson, S. C., Gordon, C. L., Christo, S. N., Klenerman, P., & Mackay, L. K. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0359-1 · Cited by 111
Engineering approaches for studying immune-tumor cell interactions and immunotherapy
Shelton, S. E., Nguyen, H. T., Barbie, D. A., & Kamm, R. D. (2021) · iScience · doi:10.1016/j.isci.2020.101985 · Cited by 93
The effects of age and systemic metabolism on anti-tumor T cell responses
Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69
“Cytotoxic effector CD8+ T cells can directly kill cells that present their cognate antigen through cytotoxic molecules, like granzyme B (GzmB) and perforin, and also secrete pro- inflammatory cytokines, like interferon (IFN)-g and tumor necrosis factor (TNF)-a (Farhood et al., 2019; Figure 1).”
Background3D Immunocompetent Organ‐on‐a‐Chip Models
Maharjan, S., Cecen, B., & Zhang, Y. S. (2020) · Small Methods · doi:10.1002/smtd.202000235 · Cited by 62
Tang, X., Deng, B., Zang, A., He, X., Zhou, Y., Wang, D., Li, D., Dai, X., Chen, J., Zhang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940577 · Cited by 39
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
FURIN regulates cytotoxic T-lymphocyte effector function and memory cell transition in mice
Ojanen, M. J. T., Caro, F. M., Aittomäki, S., Ploquin, M. J., Ortutay, Z., Pekkarinen, M., Kesseli, J., Vähätupa, M., Määttä, J., Nykter, M., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202250246 · Cited by 10
Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis
Charbel, A., Tavernar, L., Albrecht, T., Brinkmann, F., Verheij, J., Roos, E., Vogel, M. N., Köhler, B., Springfeld, C., Brobeil, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01933-0 · Cited by 11
Shin, S., Bae, G.-H., Park, J. D., Koh, E.-Y., Ko, S., Han, J., Park, C. G., Kim, D.-H., Na, K., & Park, W. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124002 · Cited by 8
Metadata
- Authors
- Farhood, B., Najafi, M., & Mortezaee, K.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2018-11-22
- Volume
- 234
- Issue
- 6
- Pages
- 8509-8521
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2905098668
- Cited by
- 1,658
- References
- 99
- FWCI
- 30.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.